Clik here to view.
Crown Bioscience Opens Singapore Laboratory and Establishes Local Commercial...
SAN DIEGO Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the opening of a new site in Singapore to expand the company’s capacity to...
View ArticleClik here to view.
Astellas and Seagen Announce China’s National Medical Products Administration...
TOKYO & BOTHELL, Wash. Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq: SGEN) today announced that the Center for Drug Evaluation...
View ArticleClik here to view.
InnoCare Announces First Subject Dosed in Clinical Trial of BCL2 Inhibitor...
BEIJING InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first subject has been...
View ArticleClik here to view.
Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for...
GUANGZHOU, China Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stage pharmaceutical company, today announced that dosing has begun in a Phase 1 clinical study evaluating BAT8007, an...
View ArticleClik here to view.
Orum Therapeutics Announces Three Presentations at AACR 2023
BOSTON & DAEJEON, South Korea Orum Therapeutics, Inc. (“Orum”), a private biotechnology company pioneering the development of tumor-directed targeted protein degraders (TPDs), today announced...
View ArticleClik here to view.
Exscientia宣布扩大其精准抗肿瘤产品线
英格兰牛津 (美国商业资讯)– Exscientia plc (Nasdaq: EXAI)今天发布两款新的全权拥有的精准抗肿瘤开发候选药物，即LSD1抑制剂EXS74539 (‘539)和MALT1蛋白酶抑制剂EXS73565...
View ArticleClik here to view.
欧洲麻醉学和重症监护学会(ESAIC)推荐无创连续血红蛋白监测
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天宣布，欧洲麻醉学和重症监护学会(ESAIC)发布的最新指南强调了无创的连续血红蛋白(Hb)监测在指导临床医生管理围手术期出血方面的价值。该指南参考了采用Masimo SpHb®等技术的临床研究，指出“使用无创Hb监测方法可能是一种连续监测Hb浓度且不会造成额外累积失血的实用方法。”1...
View ArticleClik here to view.
Clik here to view.
Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and...
View ArticleClik here to view.
欧州麻酔・集中治療学会（ESAIC）が非侵襲的・連続的ヘモグロビンモニタリングを推奨
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、欧州麻酔・集中治療学会（ESAIC）が発表した最新のガイドラインで、医師による周術期の出血管理を支える上で、非侵襲的・連続的ヘモグロビン（Hb）モニタリングが持つ価値が強調されていると発表しました。ガイドラインは、Masimo...
View ArticleClik here to view.
Exscientia将于2023年3月23日公布2022年全年业绩
英格兰牛津 (美国商业资讯)–Exscientia plc (Nasdaq: EXAI)将于2023年3月23日（周四）美国市场开盘前公布截至2022年12月31日的第四季度及全年财务业绩。公司将于格林尼治标准时间中午12:30/美国东部夏令时间上午8:30举行电话会议和网络直播，介绍最新业务情况并回顾财务业绩。...
View ArticleClik here to view.
エクセンシアが2022年通期の財務業績を2023年3月23日に発表
英オックスフォード （ビジネスワイヤ） — エクセンシア（Nasdaq：EXAI）は、2022年12月31日に終了した第4四半期および通期の財務業績を2023年3月23日（木）の米国市場開始前に発表します。午後0時30分（GMT）／午前8時30分（米東部夏時間）から、当社は電話会議とウェブキャストを実施し、事業の最新情報と財務業績について説明します。...
View ArticleClik here to view.
Exscientia将在AACR上呈报数据，重点介绍产品线和精准医疗平台
英格兰牛津 (美国商业资讯)– Exscientia plc (Nasdaq: EXAI)今天宣布，美国癌症研究学会(AACR) 2023年会已接受公司的四份摘要用于壁报展示，会议将于2023年4月14日至19日在佛罗里达州奥兰多奥兰治县会议中心召开。上述摘要将重点介绍Exscientia旗下精准发现、设计和个体化医疗相关方法中的各个组成部分，以及计划中的临床创新。...
View ArticleClik here to view.
Patritumab Deruxtecan Continues to Show Encouraging Clinical Activity in...
TOKYO & BASKING RIDGE, N.J. New data from Daiichi Sankyo’s (TSE: 4568) patritumab deruxtecan (HER3-DXd) from two early trials in patients with previously treated EGFR-mutated metastatic...
View ArticleClik here to view.
Clik here to view.
BIO KOREA 2023: Registration Now Open for Business Partnering
SEOUL, South Korea The Korea Health Industry Development Institute (KHIDI, President: Cha Soon-do) and Chungcheongbuk-do (Governor: Kim Young-hwan) invite companies to participate in the Business...
View ArticleClik here to view.
Theramex Enters Into an Exclusive Licensing Agreement With Radius Health Inc,...
LONDON Theramex, a leading global speciality pharmaceutical company dedicated to women’s health, has entered into an exclusive licensing agreement with Radius Health, Inc., for the rights to...
View ArticleClik here to view.
Prestige Biopharma Receives FDA Fast Track Designation for PBP1510 in the...
SINGAPORE Prestige Biopharma has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for PBP1510 (International Non-proprietary name: Ulenistamab), in the treatment of...
View ArticleClik here to view.
BeiGene Enters New Phase to Expand US Manufacturing and R＆D Footprint in New...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, is entering a new phase as it continues to build its U.S....
View ArticleClik here to view.
PeptiDream Announces Nomination of Second Peptide Radiopharmaceutical...
KANAGAWA, Japan PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter “PeptiDream”) (Tokyo: 4587) today announced the nomination...
View Article